Study identifier:D822FC00003
ClinicalTrials.gov identifier:NCT04380688
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
COVID-19
Phase 2
No
Acalabrutinib
All
62
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2022 by AstraZeneca
AstraZeneca
Acerta Pharma B.V.
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Location
Location
Bethesda, MD, United States, 20892-1374
Location
Buffalo, NY, United States, 14263
Location
Hackensack, NJ, United States, 07601
Location
Baltimore, MD, United States, 21287
Location
Louisville, KY, United States, 40207
Location
Washington, DC, United States, 20010
Location
Albany, NY, United States, 12208
Location
Philadelphia, PA, United States, 19140
Arms | Assigned Interventions |
---|---|
Experimental: Arm 1 Acalabrutinib+ Best Supportive Care | Drug: Acalabrutinib Acalabrutinib administered orally |
No Intervention: Arm 2 Best Supportive Care | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.